Ozempic Slows Kidney Disease, Cuts Death Risk in Type 2 Diabetes

Key takeaways:

• People with type 2 diabetes and chronic kidney disease who took Ozempic (semaglutide) slowed the progression of kidney disease by 24% and cut their risk of death from kidney disease.
• Patients who took Ozempic versus placebo also cut their risk of major heart problems by 18%.
• The latest: A new analysis showed that semaglutide also reduced the chances of experiencing heart failure or death from cardiovascular causes.

• More specifically, data showed that semaglutide decreased the overall likelihood of the following, regardless of the severity of diabetes-related kidney disease: 

  • Either serious heart failure for the first time or cardiovascular death, by 27%
  • Heart failure events, by 27%
  • Cardiovascular death, by 29%